Portal de Periódicos da CAPES

The San Antonio Breast Cancer Symposium

2011; Elsevier BV; Volume: 11; Issue: 1 Linguagem: Inglês

10.3816/cbc.2011.n.002

1938-0666

Tristin Abair, Susan Peck, Joyce O’Shaughnessy,

HER2/EGFR in Cancer Research

The interaction between breast cancer cells and the bone microenvironment is complex, and several studies have suggested that bisphosphonates may possess anti-tumor properties through disruption of this interplay. In the ABCSG-12 trial, the addition of zoledronic acid to adjuvant endocrine treatment (the luteinizing hormone-releasing hormone [LHRH] agonist goserelin combined with either tamoxifen or anastrozole) significantly improved recurrence-free survival (hazard ratio [HR], 0.65 [95% CI, 0.46-0.92]; P = .01) and disease-free survival (DFS; HR, 0.64 [95% CI, 0.46-0.91]; P = .01) in premenopausal patients, with no significant difference in overall survival (OS), compared with endocrine treatment without zoledronic acid. 1 Gnant M Mlineritsch B Schippinger W et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med. 2009; 360: 679-691 Crossref PubMed Scopus (939) Google Scholar Exploratory data from the adjuvant Z-FAST and ZO-FAST studies also suggested reduced disease recurrence with upfront bisphosphonate administration compared with delayed administration, with a significant 41% reduction in the risk of DFS events in the ZO-FAST trial. 2 Brufsky A Harker G Beck JT et al. The effect of zoledronic acid on aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: The Z-FAST study 5-year final follow-up. Cancer Res. 2009; 69 (abstract 4083). Google Scholar , 3 Eidtmann H de Boer R Bundred N et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann Oncol. 2010; 21: 2188-2194 Crossref PubMed Scopus (262) Google Scholar